Achillion Pharmaceuticals Inc. (ACHN) Begins First-in-human Dosing for Hepatitis C Treatment
Achillion Pharmaceuticals Inc. today announced that it has begun dosing in a phase 1 clinical trial of ACH-2684 for the treatment of chronic hepatitis C virus (HCV) infection. “This first-in-human clinical trial will be instrumental in establishing the safety profile of ACH-2684 in humans,” Elizabeth A. Olek, D.O., vice president and chief medical officer of Achillion stated in the press release. “It will also provide Achillion with important preliminary efficacy data against HCV genotypes 1 and 3, and help us to select doses for subsequent clinical development.” The clinical study is a randomized, double-blind, placebo-controlled trial in which scientists will…